uniQure N.V. (QURE) is transitioning its business model beyond HEMGENIX-related economics, focusing on regulatory speed and expanding its gene therapy portfolio. The company’s Huntington’s disease therapy, AMT-130, has received significant FDA designations, indicating a potential for accelerated approval based on existing trial data.
As of March 31, 2026, uniQure reported $586.6 million in cash, sufficient to fund operations through the second half of 2029. This financial positioning supports ongoing regulatory efforts and clinical studies, but the discontinuation of AMT-162 for ALS has increased reliance on AMT-130 as the company navigates inherent risks in gene therapy innovation.
Recently published early data from AMT-260, targeting mesial temporal lobe epilepsy, demonstrated a 79% to 100% reduction in seizures in some patients, showcasing uniQure’s commitment to expanding its central nervous system disorder portfolio.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
